NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free NRIX Stock Alerts $14.70 +0.16 (+1.10%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$14.17▼$15.3650-Day Range$7.77▼$15.6652-Week Range$4.22▼$16.11Volume1.31 million shsAverage Volume809,639 shsMarket Capitalization$718.68 millionP/E RatioN/ADividend YieldN/APrice Target$20.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nurix Therapeutics alerts: Email Address Nurix Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside38.8% Upside$20.40 Price TargetShort InterestHealthy13.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 5 Articles This WeekInsider TradingSelling Shares$100,256 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.26) to ($3.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector479th out of 938 stocksPharmaceutical Preparations Industry218th out of 423 stocks 4.4 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.40, Nurix Therapeutics has a forecasted upside of 38.8% from its current price of $14.70.Amount of Analyst CoverageNurix Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.11% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 6.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 2.5 News and Social Media Coverage News SentimentNurix Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nurix Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 25 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows5 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,256.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($3.26) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Nurix Therapeutics Stock (NASDAQ:NRIX)Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More NRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Stock News HeadlinesMarch 25, 2024 | globenewswire.comNurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)March 20, 2024 | globenewswire.comNurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 20, 2024 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) & Takeda Pharmaceutical (NYSE:TAK) Head to Head ContrastMarch 12, 2024 | finance.yahoo.comNRIX Oct 2024 20.000 callMarch 12, 2024 | markets.businessinsider.comNurix Therapeutics Gains Analyst Confidence with Advancements in Clinical Programs and Strategic Focus on NHLMarch 12, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Nurix Therapeutics Following FDA’s Lift of Clinical Hold on Cancer Drug NX-2127March 11, 2024 | markets.businessinsider.comAnalyst Scoreboard: 7 Ratings For Nurix TherapeuticsMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 11, 2024 | marketwatch.comNurix Therapeutics: FDA Lifts Partial Clinical Hold on NX-2127 StudyMarch 11, 2024 | markets.businessinsider.comNurix Therapeutics: FDA Lifts Partial Clinical Hold On NX-2127 Phase 1 TrialMarch 11, 2024 | finance.yahoo.comNurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialMarch 6, 2024 | markets.businessinsider.comNurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingMarch 6, 2024 | finance.yahoo.comNurix Therapeutics to Participate in Upcoming Investor ConferencesMarch 6, 2024 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesFebruary 29, 2024 | markets.businessinsider.comNurix Therapeutics’ Promising Outlook: Buy Rating Affirmed Amidst Strategic Development and Market PositioningFebruary 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Cochlear Limited (OtherCHEOF) and Nurix Therapeutics (NRIX)February 22, 2024 | benzinga.comNurix Therapeutics Stock (NASDAQ:NRIX) Earnings Dates and Earning CallsFebruary 20, 2024 | msn.com3 Best Stocks to Buy Now, 2/19/2024, According to Top AnalystsFebruary 18, 2024 | finanznachrichten.deNurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateFebruary 17, 2024 | finance.yahoo.comNurix Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 16, 2024 | finance.yahoo.comNurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical ProgressFebruary 16, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)February 16, 2024 | markets.businessinsider.comDecoding 4 Analyst Evaluations For Nurix TherapeuticsFebruary 16, 2024 | msn.comNurix Therapeutics GAAP EPS of -$0.77 misses by $0.38, revenue of $15.2M misses by $21.34MFebruary 15, 2024 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue EstimatesFebruary 15, 2024 | finance.yahoo.comNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateSee More Headlines Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/28/2024Next Earnings (Estimated)4/11/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees284Year FoundedN/APrice Target and Rating Average Stock Price Target$20.40 High Stock Price Target$31.00 Low Stock Price Target$10.00 Potential Upside/Downside+38.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,950,000.00 Net Margins-186.98% Pretax Margin-186.98% Return on Equity-59.47% Return on Assets-41.59% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual Sales$76.99 million Price / Sales9.33 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book3.56Miscellaneous Outstanding Shares48,890,000Free Float45,374,000Market Cap$718.68 million OptionableOptionable Beta2.04 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Arthur T. Sands M.D. (Age 62)Ph.D., CEO, President & Director Comp: $910.98kMr. Johannes Van Houte (Age 58)Chief Financial Officer Comp: $650.74kDr. Gwenn M. Hansen Ph.D. (Age 53)Chief Scientific Officer Comp: $661.19kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardMr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSenior Accounting ManagerDr. Christine Ring J.D. (Age 59)Ph.D., Chief Legal Officer & Chief Compliance Officer Comp: $595.83kMr. Eric C. Schlezinger J.D. (Age 57)Chief People Officer Dr. Jason Kantor Ph.D.Chief Business OfficerMore ExecutivesKey CompetitorsCureVacNASDAQ:CVACAcelyrinNASDAQ:SLRNSilence TherapeuticsNASDAQ:SLNSavaraNASDAQ:SVRAMineralys TherapeuticsNASDAQ:MLYSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 116,748 shares on 3/11/2024Ownership: 5.314%Wellington Management Group LLPBought 60,271 shares on 3/5/2024Ownership: 0.420%Goldman Sachs Group Inc.Sold 81,626 shares on 3/1/2024Ownership: 0.577%Price T Rowe Associates Inc. MDBought 11,988 shares on 2/16/2024Ownership: 4.928%Houte Hans VanSold 6,812 sharesTotal: $68,256.24 ($10.02/share)View All Insider TransactionsView All Institutional Transactions NRIX Stock Analysis - Frequently Asked Questions Should I buy or sell Nurix Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NRIX shares. View NRIX analyst ratings or view top-rated stocks. What is Nurix Therapeutics' stock price target for 2024? 5 brokers have issued 12-month price objectives for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they expect the company's share price to reach $20.40 in the next year. This suggests a possible upside of 38.8% from the stock's current price. View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts. How have NRIX shares performed in 2024? Nurix Therapeutics' stock was trading at $10.32 at the start of the year. Since then, NRIX shares have increased by 42.4% and is now trading at $14.70. View the best growth stocks for 2024 here. When is Nurix Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 11th 2024. View our NRIX earnings forecast. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings results on Thursday, February, 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.26. The company had revenue of $15.16 million for the quarter, compared to analysts' expectations of $30.66 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 59.47% and a negative net margin of 186.98%. What ETF holds Nurix Therapeutics' stock? ARK Genomic Revolution ETF holds 2,333,922 shares of NRIX stock, representing 0.94% of its portfolio. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR). When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Nurix Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (6.59%), Wasatch Advisors LP (5.67%), Vanguard Group Inc. (5.36%), Vanguard Group Inc. (5.31%), Price T Rowe Associates Inc. MD (4.93%) and Price T Rowe Associates Inc. MD (4.93%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRIX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.